Orexigen Therapeutics, Inc. (OREX) Tops Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts OREX Hot Sheet
Join SI Premium – FREE
Orexigen Therapeutics, Inc. (NASDAQ: OREX) reported Q2 EPS of ($0.16), $0.04 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $857 thousand versus the consensus estimate of $740 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- Prenetics Global (PRE) Tops Q2 EPS by 18c
- Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
